コンテンツへスキップ
Merck

933589

Sigma-Aldrich

NanoFabTx NanoFlash PEG Lipid Mix

for CIJ synthesis of PEGylated liposomes

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352211
NACRES:
NA.21

品質水準

保管温度

−20°C

アプリケーション

NanoFabTx NanoFlash PEG Lipid Mix a ready-to-use nanoformulation lipid blend that includes lyophilized lipids and step-by-step instructions for synthesizing PEGylated liposomes for small molecule drug delivery applications. Lipid-based formulations are widely used for drug delivery and enable improved therapeutic efficacy of a range of drug types PEGylated liposomes are capable of encapsulating both hydrophilic and lipophilic compounds and are an effective mechanism to increase the efficiency of drug delivery by prolonging the lifetime of the drug-encapsulated liposome.
This lipid mix has been curated and designed for flash nanoprecipitiaton (FNP) synthesis using a confined impingement jet (CIJ) mixer, such as the NanoFabTx NanoFlash CIJ Mixer, and detailed step-by-step instructions are provided.

特徴および利点

  • A ready-to-use nanoformulation lipid blend for the synthesis of PEGylated liposomes
  • Step-by-step protocols (extrusion and microfluidics) developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible liposomes
  • Optimized to make liposomes around 100 nm with low polydispersity
  • Optimized lipid blend for stealth PEGylated liposomes for small molecule encapsulation
The NanoFabTx- PEG Lipid Mix provides reagents and protocols for extrusion and microfluidics to synthesize liposomes for drug delivery research application. This reagent kit can be combined with the NanoFabTx Microfluidic - nano device kit (Cat.No. 91153) for microfluidic synthesis of PEGylated liposomes. Comprehensive protocols for liposome synthesis are included:

  • A lipid film hydration and extrusion protocol
  • A microfluidics protocol using commercial platforms or syringe pumps
The microfluidics protocol included with this product uses the NanoFabTx device kit (911593). These kits come with the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

法的情報

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

保管分類コード

11 - Combustible Solids

WGK

WGK 3


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

933589-100MG:
933589-100MG-PW:
933589-BULK:
933589-VAR:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Which polymers can make nanoparticulate drug carriers long-circulating?
VP, Torchilin, et al.
Advanced Drug Delivery Reviews, 16, 141?155-141?155 (1995)
Jing Han et al.
Journal of pharmaceutical sciences, 101(10), 4018-4023 (2012-07-11)
Johnson and Prud'homme (2003. AICHE J 49:2264-2282) introduced the confined impingement jets (CIJ) mixer to prepare nanoparticles loaded with hydrophobic compounds (e.g., drugs, inks, fragrances, or pheromones) via flash nanoprecipitation (FNP). We have modified the original CIJ design to allow
Yunes Panahi et al.
Artificial cells, nanomedicine, and biotechnology, 45(4), 788-799 (2017-03-11)
Liposome is a new nanostructure for the encapsulation and delivery of bioactive agents. There are a lot of bioactive materials that could be incorporated into liposomes including cosmetics, food ingredients, and pharmaceuticals. Liposomes possess particular properties such as biocompatibility, biodegradability;
D Papahadjopoulos et al.
Proceedings of the National Academy of Sciences of the United States of America, 88(24), 11460-11464 (1991-12-15)
The results obtained in this study establish that liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid have a pronounced effect on liposome tissue distribution and can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs. This effect
Daryl C Drummond et al.
Cancer research, 66(6), 3271-3277 (2006-03-17)
Liposome formulations of camptothecins have been actively pursued because of the potential for significant pharmacologic advantages from successful drug delivery of this important class of anticancer drugs. We describe nanoliposomal CPT-11, a novel nanoparticle/liposome construct containing CPT-11 (irinotecan) with unprecedented

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)